People · Operator
Named in public records as an officer, director or promoter · active 2012–2019 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
| Iconic Therapeutics Inc | — | Biotechnology | Series C | $79.0M | $533.7M | 2014 |
| River Vision Development Corp. | — | Biotechnology | Series B | $33.1M | $198.4M | 2012 |
| Curzion Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.1M | 2019 |
Johan Kordel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Johan Kordel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Mathers | 2 | 11 |
| Edward Mathers | 1 | 12 |
| Todd Foley | 1 | 12 |
| Brian Gallagher | 1 | 11 |
| Michael Grey | 1 | 10 |
| ANAND MEHRA | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Bruce Cohen | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Bruce Robertson | 1 | 7 |
| William Greene | 1 | 6 |
| Alan Fuhrman | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Paul Grint | 1 | 5 |
| Elaine Heron | 1 | 3 |
| Karen Talmadge | 1 | 3 |
| Susan Dube | 1 | 3 |
| Brian M Gallagher | 1 | 3 |
| Julia Gregory | 1 | 3 |
| Chrysa Mineo | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.